Related Experiment Video

Updated: Jul 4, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Circulating hematopoietic stem cells in patients with choroidal neovascularization secondary to pathologic myopia

M Sasahara1, A Otani, Y Yodoi

  • 1Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Eye (London, England)
|June 21, 2008
PubMed

Insights

Circulating hematopoietic stem cells (HSCs) may be lower in patients with bilateral choroidal neovascularization (CNV) secondary to pathologic myopia. These findings suggest HSCs play a systemic role in bilateral CNV development.

Area of Science:

  • Ophthalmology
  • Stem Cell Biology
  • Regenerative Medicine

Background:

  • Emerging evidence suggests circulating hematopoietic stem cells (HSCs) influence choroidal neovascularization (CNV) pathogenesis.
  • The specific role of HSCs in human CNV, particularly in pathologic myopia (PM), remains unclear.
  • This study investigates the involvement of HSCs in CNV secondary to PM.

Purpose of the Study:

  • To investigate the role of circulating hematopoietic stem cells (HSCs) in the pathogenesis of choroidal neovascularization (CNV) in patients with pathologic myopia (PM).
  • To explore potential systemic factors contributing to the development of bilateral CNV in PM patients.

Main Methods:

  • Clinical documentation of 78 patients with CNV in PM.
  • Experimental analysis of HSCs in 35 patients and 28 age-matched controls using ex vivo culture.
  • Comparison of circulating endothelial cell colony-forming units (CFU-ECs) between unilateral and bilateral CNV groups.

Main Results:

  • Colony-forming units of endothelial cells (CFU-ECs) were significantly lower in patients with bilateral CNV compared to unilateral CNV (13.8±3.7 vs 45.9±7.8, P<0.001).
  • No significant differences in systemic characteristics were observed between unilateral and bilateral CNV groups.
  • No statistically significant local ocular factors were identified that correlated with CNV occurrence.

Conclusions:

  • Circulating HSCs may function as a systemic factor contributing to the bilateral involvement of CNV in patients with PM.
  • Further prospective and longitudinal studies are warranted to elucidate the precise role of HSCs in CNV pathogenesis.
Abstract

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.